WO2005113588A3 - Methods and compositions related to smad anchors for tgfb/bmp receptor activaton - Google Patents

Methods and compositions related to smad anchors for tgfb/bmp receptor activaton Download PDF

Info

Publication number
WO2005113588A3
WO2005113588A3 PCT/US2005/001128 US2005001128W WO2005113588A3 WO 2005113588 A3 WO2005113588 A3 WO 2005113588A3 US 2005001128 W US2005001128 W US 2005001128W WO 2005113588 A3 WO2005113588 A3 WO 2005113588A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
activaton
tgfb
smad
anchors
Prior art date
Application number
PCT/US2005/001128
Other languages
French (fr)
Other versions
WO2005113588A2 (en
Inventor
Xu Cao
Weibin Shi
Original Assignee
Uab Research Foundation
Xu Cao
Weibin Shi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation, Xu Cao, Weibin Shi filed Critical Uab Research Foundation
Publication of WO2005113588A2 publication Critical patent/WO2005113588A2/en
Publication of WO2005113588A3 publication Critical patent/WO2005113588A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is methods and compositions related to modulation of signaling in the transforming growth factor-β (TGFβ) superfamily. Such signaling is important in a wide range of disorders including cancer, developmental disorders, and bone diseases, as well as in bone growth, development, and repair.
PCT/US2005/001128 2004-01-12 2005-01-12 Methods and compositions related to smad anchors for tgfb/bmp receptor activaton WO2005113588A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53591304P 2004-01-12 2004-01-12
US60/535,913 2004-01-12

Publications (2)

Publication Number Publication Date
WO2005113588A2 WO2005113588A2 (en) 2005-12-01
WO2005113588A3 true WO2005113588A3 (en) 2006-02-23

Family

ID=35428912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/001128 WO2005113588A2 (en) 2004-01-12 2005-01-12 Methods and compositions related to smad anchors for tgfb/bmp receptor activaton

Country Status (1)

Country Link
WO (1) WO2005113588A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2688299A1 (en) * 2007-05-29 2008-12-18 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005360A1 (en) * 1998-07-20 2000-02-03 Hsc Research And Development Limited Partnership Sara proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005360A1 (en) * 1998-07-20 2000-02-03 Hsc Research And Development Limited Partnership Sara proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENNETT DAIMARK ET AL: "PP1 binds Sara and negatively regulates Dpp signaling in Drosophila melanogaster.", NATURE GENETICS. AUG 2002, vol. 31, no. 4, August 2002 (2002-08-01), pages 419 - 423, XP002358473, ISSN: 1061-4036 *
SHI WEIBIN ET AL: "GADD34-PP1c recruited by Smad7 dephosphorylates TGFbeta type I receptor.", JOURNAL OF CELL BIOLOGY, vol. 164, no. 2, 19 January 2004 (2004-01-19), pages 291 - 300, XP002358474, ISSN: 0021-9525 *
TSUKAZAKI T ET AL: "SARA, a FYVE domain protein that recreuits Smad2 to the TGF-beta receptor", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 95, no. 6, 11 December 1998 (1998-12-11), pages 779 - 791, XP002124598, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2005113588A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2001083755A3 (en) Human anti-cd40 antibodies and methods of making and using same
WO2004080377A3 (en) Kcnq channel modulating compounds and their pharmaceutical use
AU2003283136A1 (en) Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
MXPA06014721A (en) Novel alkynyl derivatives as modulators of metabotropic glutamate receptors.
IL169690A0 (en) Uses of anti-insulin-like growth factor i receptor antibodies
EP2364705A3 (en) Modulators of muscarinic receptors
WO2004113513A3 (en) Methods and compositions for modulating stem cell growth and differentiation
WO2003029262A3 (en) The human mob-5 (il-24) receptors and uses thereof
WO2004084453A3 (en) METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
CA2523831A1 (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
WO2003053340A3 (en) Antisense modulation of connective tissue growth factor expression
EP2327709A3 (en) Modulation of glucagon receptor expression
WO2005115392A3 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
WO2006105035A3 (en) Muscarinic modulators
WO2006058294A3 (en) Modulators of muscarinic receptors
WO2004060310A8 (en) Human growth hormone crystals and methods for preparing them
WO2004048534A3 (en) Modulation of cytokine-inducible kinase expression
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
WO2003052072A3 (en) Antisense modulation of estrogen receptor alpha expression
WO2004053101A3 (en) Methods and compositions using compounds from fetal cells and tissues to improve condition of skin
WO2006063031A3 (en) Allelic variants of human factor viii
WO2003024408A8 (en) Compositions and methods involved in bone growth
WO2006002082A3 (en) Carbazole formulations for the treatment of psoriasis and angiogenesis
WO2006058303A3 (en) Modulators of muscarinic receptors
EP1736470A3 (en) Pyrimidine derivatives as CB2 cannabinoid receptor modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase